PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS
    21.
    发明申请
    PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS 有权
    吡唑并嘧啶PDE 10抑制剂

    公开(公告)号:US20130137707A1

    公开(公告)日:2013-05-30

    申请号:US13816568

    申请日:2011-09-26

    IPC分类号: A61K31/519 C07D487/04

    摘要: The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

    摘要翻译: 本发明涉及可用作治疗与磷酸二酯酶10(PDE10)相关的中枢神经系统疾病的治疗剂的吡唑并嘧啶化合物。 本发明还涉及这些化合物用于治疗神经和精神疾病如精神分裂症,精神病或亨廷顿病以及与纹状体功能减退或基底神经节功能障碍相关的疾病的用途。

    Mitotic kinesin inhibitors
    23.
    发明授权
    Mitotic kinesin inhibitors 失效
    有丝分裂驱动蛋白抑制剂

    公开(公告)号:US07629373B2

    公开(公告)日:2009-12-08

    申请号:US11887800

    申请日:2006-04-03

    IPC分类号: A61K31/415 C07D231/06

    CPC分类号: C07D231/06

    摘要: The present invention relates to fluorinated dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

    摘要翻译: 本发明涉及可用于治疗细胞增殖性疾病,用于治疗与KSP驱动蛋白活性相关的疾病和用于抑制KSP驱动蛋白的氟化二氢吡唑化合物。 本发明还涉及包含这些化合物的组合物,以及使用它们治疗哺乳动物癌症的方法。

    Mitotic Kinesin Inhibitors
    25.
    发明申请
    Mitotic Kinesin Inhibitors 失效
    有丝分裂驱动蛋白抑制剂

    公开(公告)号:US20080194582A1

    公开(公告)日:2008-08-14

    申请号:US11886274

    申请日:2006-03-10

    CPC分类号: C07D231/06

    摘要: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

    摘要翻译: 本发明涉及可用于治疗细胞增殖性疾病,治疗与KSP驱动蛋白活性相关的疾病和用于抑制KSP驱动蛋白的二氢吡唑化合物。 本发明还涉及包含这些化合物的组合物,以及使用它们治疗哺乳动物癌症的方法。

    Pyridyl piperidine orexin receptor antagonists
    27.
    发明授权
    Pyridyl piperidine orexin receptor antagonists 有权
    吡啶基哌啶食欲素受体拮抗剂

    公开(公告)号:US08569311B2

    公开(公告)日:2013-10-29

    申请号:US13568242

    申请日:2012-08-07

    IPC分类号: C07D401/14 A61K31/4525

    摘要: The present invention is directed to pyridyl piperidine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

    摘要翻译: 本发明涉及作为食欲素受体的拮抗剂的吡啶基哌啶化合物,其可用于治疗或预防涉及食欲肽受体的神经和精神病症和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及食欲肽受体的疾病中的用途。

    Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors
    28.
    发明授权
    Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors 失效
    烷氧基四氢 - 吡啶并嘧啶PDE10抑制剂

    公开(公告)号:US08492392B2

    公开(公告)日:2013-07-23

    申请号:US13320038

    申请日:2010-05-24

    IPC分类号: A61K31/519

    CPC分类号: C07D471/04 C07D519/00

    摘要: The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds of formula I, which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

    摘要翻译: 本发明涉及式I的烷氧基四氢 - 吡啶并嘧啶化合物,其可用作治疗与磷酸二酯酶10(PDE10)相关的中枢神经系统疾病的治疗剂。 本发明还涉及这些化合物用于治疗神经和精神疾病如精神分裂症,精神病或亨廷顿病以及与纹状体功能减退或基底神经节功能障碍相关的疾病的用途。

    2,5-disubstituted morpholine orexin receptor antagonists
    29.
    发明授权
    2,5-disubstituted morpholine orexin receptor antagonists 有权
    2,5-二取代吗啉食欲肽受体拮抗剂

    公开(公告)号:US08466281B2

    公开(公告)日:2013-06-18

    申请号:US13124884

    申请日:2009-10-15

    IPC分类号: C07D265/30 A61K31/535

    摘要: The present invention is directed to 2,5-disubstituted morpholine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

    摘要翻译: 本发明涉及作为食欲素受体的拮抗剂的2,5-二取代的吗啉酰胺化合物,其可用于治疗或预防涉及食欲肽受体的神经和精神病症和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及食欲肽受体的疾病中的用途。